Conference Day Two

Thursday 19th October 2023

8:00 am Morning Networking Coffee

8:50 am Chair’s Opening Remarks

Looking Beyond NK Allogeneic Therapies with Cell Engager & Combined Modality Strategies

9:00 am Case Study: Leveraging the Full Immunity Cycle: ICE® to Engage the Innate & Adaptive Immune System for Effective Anti-Tumoural Responses

  • Joachim Koch Vice President and Head Discovery Research & Translational Immunology, Affimed


  • Sharing data of the multi-layered immune response of Affimed’s ICE® as mono- and combination therapy
  • Outlining the development of an AB-101 NK cell product combination with AFM13 for CD30+ malignancies, such as HL and CD30-positive PTCL patients
  • Highlighting early data from the combination of AFM24 with the checkpoint inhibitor atezolizumab in the treatment EGFR+ solid tumours
  • Providing an update of the clinical progress of the AFM28 monotherapy study in patients with CD123+ AML

9:30 am Case Study: Developing Effective Innate Cell Engager Strategies in Haematological Malignancies

  • Helgi van de Velde Vice President, Head of Hematologic Malignancies Strategies and Late Development, Sanofi


  • Dual NK cell engagement to enhance antitumoural activity
  • Trifunctional NK cell engager in AML
  • Trifunctional NK cell engager in multiple myeloma

10:00 am Innate Cells, an Alternative & Power Player in the Arsenal of Immunotherapy for Cancer Patients


  • Activation of the innate immunity as alternative strategy for immuno-oncology
  • Use of the innate cell engager to activate myeloid cells preferentially in the tumour microenvironment
  • Activation of multiple immune cell populations to achieve stronger antitumour activity

10:30 am Morning Refreshment Break & Networking

Re-Imagining Predictive Modelling to Break Translational Barriers in Innate Cell Therapy Development

11:00 am ROUNDTABLE DISCUSSION: Overcoming Preclinical Modelling Pitfalls in Innate Cell Therapy Development to Facilitate Translation into the Clinic

  • Michelle Morrow Senior Vice President & Head of Research, F-star Biotechnology Ltd.


With reduced conservation between mice and human innate immunity, the ability to obtain representative preclinical data that generates reliable predictors of clinical efficacy has been hard to achieve for the innate immune therapy industry. This roundtable provides an opportunity for the industry to discuss ways to overcome defunct preclinical in vivo models and propel innate immunotherapies into the clinic and beyond.

12:00 pm Networking Lunch

Harnessing the Power of Myeloid Cells to Achieve Clinical Efficacy in the Next Generation of Innate Cell Therapies

1:00 pm Case Study: Utilising Immunomodulatory Alpha Neutrophils to Promote Solid Tumour Infiltration

  • Alex Blyth Chief Executive Officer, LiFT Biosciences


  • Exploiting chemokine signalling to promote solid tumour infiltration
  • Reprogramming immunosuppressive TME to recruit a wider immune response via favourable cytokine production
  • Engaging the adaptive immune system through upregulatiuon of 4-1BB and OX-40 to promote persistance

1:30 pm Case Study: Engineered Macrophage Immunotherapy: CARs & Beyond


  • Development of CAR-M immunotherapy
  • First-in-human CAR-M phase I clinical data
  • Next generation approaches

2:00 pm Afternoon Refreshment Break & Networking

2:30 pm Exploiting the Phenotypic Plasticity of Macrophages in Disease Indications Outside Oncology

  • Keith Sutton Director of Preclinical Development, Resolution Therapeutics


  • Using macrophages to reprogramme the inflammatory niche
  • Targeting of macrophage therapies
  • Engineering the macrophage phenotype; getting from autologous to allogeneic

3:00 pm PANEL DISCUSSION: Leveraging Different Innate Cell Types for Therapeutic Efficacy in Oncology & Beyond


With significant work taking place to understand the potential of novel innate cell types such as macrophages, neutrophils and iNKT cells for treatment applications in Oncology, attention also turns to the therapeutic application of innate cells for other important diseases such as inflammatory, autoimmune and fibrosis indications.

This panel discussion will cover:

  • Understanding the key therapeutic settings and requirements for innate cell applications in oncology and beyond
  • Discussing screening procedures to streamline dosing schedules in oncology
  • Building effective methods for patient stratification in non-oncology indications
  • Comparing combined modality strategies in oncology and non-oncology indications
  • Understanding the need for robust clinical endpoints to inform drug development outside of S9 for mon-oncology indications

3:45 pm Chair’s Closing Remarks

4:00 pm End of Day 2